Trial · NCT00423735
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Achieving 6-month Progression-free Survival (6mPFS) | Stage 1: Dasatinib 200mg/Day | 1 | participants | ||
| Number of Patients Achieving 6-month Progression-free Survival (6mPFS) | Stage 1B: Dasatinib up to 400mg/Day | 2 | participants | ||
| Number of Patients Achieving Objective Response (Partial or Complete Response) OR 6-month Progression-free Survival (6mPFS) | Stage 1: Dasatinib 200mg/Day | 1 | participants | ||
| Number of Patients Achieving Objective Response (Partial or Complete Response) OR 6-month Progression-free Survival (6mPFS) | Stage 1B: Dasatinib up to 400mg/Day | 2 | participants | ||
| Overall Survival | Stage 1: Dasatinib 200mg/Day | 6.5 | 95% Confidence Interval 3.5 to 9.5 | months | |
| Overall Survival | Stage 1B: Dasatinib up to 400mg/Day | 8.9 | 95% Confidence Interval 5.0 to 11.3 | months | |
| Treatment Response Rates at Six Months | Stage 1: Dasatinib 200mg/Day | CR or PR | 0.0 | percentage of participants | |
| Treatment Response Rates at Six Months | Stage 1B: Dasatinib up to 400mg/Day | CR or PR | 0.0 | percentage of participants | |
| Treatment Response Rates at Six Months | Stage 1: Dasatinib 200mg/Day | Stable | 19.0 | percentage of participants | |
| Treatment Response Rates at Six Months | Stage 1B: Dasatinib up to 400mg/Day | Stable | 27.6 | percentage of participants | |
| Treatment Response Rates at Six Months | Stage 1: Dasatinib 200mg/Day | Progression | 76.2 | percentage of participants | |
| Treatment Response Rates at Six Months | Stage 1B: Dasatinib up to 400mg/Day | Progression | 69.0 | percentage of participants | |
| Treatment Response Rates at Six Months | Stage 1: Dasatinib 200mg/Day | No scan done and no clinical progression reported | 4.8 | percentage of participants | |
| Treatment Response Rates at Six Months | Stage 1B: Dasatinib up to 400mg/Day | No scan done and no clinical progression reported | 3.4 | percentage of participants | |
| Progression-free Survival | Stage 1: Dasatinib 200mg/Day | 1.7 | 95% Confidence Interval 1.0 to 2.0 | months | |
| Progression-free Survival | Stage 1B: Dasatinib up to 400mg/Day | 1.8 | 95% Confidence Interval 1.2 to 2.0 | months | |
| Rate of Adverse Events | Stage 1: Dasatinib 200mg/Day | Grade 1 | 0.0 | percentage of participants | |
| Rate of Adverse Events | Stage 1B: Dasatinib up to 400mg/Day | Grade 1 | 10.3 | percentage of participants | |
| Rate of Adverse Events | Stage 1: Dasatinib 200mg/Day | Grade 2 | 14.3 | percentage of participants | |
| Rate of Adverse Events | Stage 1B: Dasatinib up to 400mg/Day | Grade 2 | 17.2 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00423735/results